Regenerative medicine company, Regeneus Ltd (ASX: RGS), announces today the granting by the Australian Patent Office of Australian patent number 2013203164. This Regeneus owned patent, Therapeutics for skin conditions, provides protection for the company’s stem cell secretions technology for the topical treatment of acne.
This important intellectual property milestone marks the first Regeneus patent to be granted in Australia.
The company’s secretions technology utilizes the molecules (including cytokines and growth factors) that are secreted by mesenchymal stem cells (MSCs). Regeneus has developed technology and protocols for the production of secretions from MSCs. It is widely recognised that the therapeutic value of MSCs is due to these secretions and that when the secretions are applied to skin, there is a localised anti-inflammatory effect, an acceleration of healing and a reduction in scarring.
The company has produced a cream currently under investigation and safety testing that incorporates the cell secretions. The company is exploring partnering options for the commercialisation of the secretions technology. Skin conditions and wound healing are one of the most promising and near term areas for cell-based regenerative medicine products. With few treatment innovations or improvements in the treatment of acne over the last 10 years, the demand for new improved acne treatments is high. Despite this, the global market for acne-based prescription treatments is over $3 Billion per annum.
Regeneus Chief Scientific Officer, Professor Graham Vesey said, "A number of our patents are in the final stages of being granted in Australia and are progressing through the overseas examination process. Our patent applications cover our product pipeline that includes our allogeneic and autologous stem cell products. The patent that has been granted is specific for the topical treatment of acne, however, we have additional patent applications in the pipeline that cover the use of the secretions technology for other skin conditions".
"A number of our patent applications were the subject of oppositions by companies in our sector. As reported at our AGM, these oppositions have now been resolved and we expect these patents to be granted in the near future."